08/11/2024  17:35:15 Chg. +2.15 Volume Bid17:35:15 Ask17:35:15 Market Capitalization Dividend Y. P/E Ratio
363.80GBX +0.59% 2.82 mill.
Turnover(GBP): 10.23 mill.
-Bid Size: - -Ask Size: - 33.75 bill.GBP - -

Business description

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. It provides oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands includes Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum.
 

Management board & Supervisory board

CEO
Brian McNamara
Management board
Tobias Hestler, Keith Choy, Filippo Lanzi, Mairéad Nayager, Lisa Paley, Franck Riot, Tamara Rogers, Bjarne Philip Tellmann, Ed Petter, Björn Timelin, Namrata Patel
Supervisory board
Sir Dave Lewis , Brian McNamara , Tobias Hestler, Mavinder Singh (Vindi) Banga , Marie-Anne Aymerich , Tracy Clarke, Dame Vivienne Cox, Asmita Dubey, Deirdre Mahlan, Bryan Supran, David (Dave) Denton
 

Company data

Name: Haleon PLC
Address: The Heights Building 5, First Floor The Heights,Surrey KT13 0NY
Phone: -
Fax: -
E-mail: -
Internet: https://www.haleon.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 31/12
Free Float: -
IPO date: -

Investor relations

Name: -
IR phone: -
IR Fax: -
IR e-mail: investor-relations@haleon.com

Company calendar

CW 10 | 05/03/2025 4th Quarter/Annual Report
 

Main Shareholders

Others
 
55.00%
Pfizer
 
32.00%
GSK
 
13.00%